Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07614984 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
NCT07614984 is a Phase 2 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 750 participants.
The verdict
NCT07614984, a Phase 2 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
Study Summary
Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C). The goals of this trial are to evaluate: * if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood * if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood * the safety and tolerability of taking MK-7262 and enlicitide alone and together
Interventions
- DRUG Enlicitide
- DRUG MK-7262
- DRUG Placebo for MK-7262
- DRUG Placebo for enlicitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-10-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07614984
The ClinicalTrials.gov registry entry for NCT07614984 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Enlicitide is the first listed.
NCT07614984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07614984 about?
NCT07614984 is a clinical study titled "A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)". Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low...
What is the current status of trial NCT07614984?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2026-06-30. Estimated completion is 2027-10-12.
What interventions are being tested in trial NCT07614984?
The interventions under investigation include: Enlicitide (DRUG), MK-7262 (DRUG), Placebo for MK-7262 (DRUG), Placebo for enlicitide (DRUG).
Who is sponsoring clinical trial NCT07614984?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.